SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
VALENCIA, Calif., May 30, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) announced today that its Board of Directors appointed Michael Castagna, Pharm.D., as Chief Executive Officer effective May 25, 2017. Dr. Castagna replaced Matthew Pfeffer, who served as both CEO and Chief Financial Officer since January 2016 and as CFO from 2008 to 2016. To facilitate an orderly transition, Mr. Pfeffer will continue with the company in an advisory capacity until the end of July 2017.
In addition, on May 25, 2017, Dr. Castagna was appointed to the board of directors of MannKind.
Kent Kresa, Chairman of the Board, said, "The Board is extremely grateful to Matt for his committed service to the company over the past nine years. Matt successfully set the foundation for the company during its transition into a commercial entity and effectively prepared Michael to be his successor.” Mr. Kresa continued, “Michael demonstrated deep commercial expertise in his prior role as MannKind’s Chief Commercial Officer as he built the capabilities from the bottom-up necessary to position Afrezza and the company for future growth. Under Michael’s leadership, new prescriptions of Afrezza have shown a steady increase since the MannKind launch and future prospects for this innovative product are strong. The Board is excited to move forward under Michael’s leadership.”
Dr. Castagna said, “I am honored to lead MannKind into its next phase of growth. Our inhaled insulin, Afrezza, is a truly differentiated brand that will help millions of people suffering from diabetes. Our relentless focus on empowering people to conquer the daily struggle of managing their diabetes will set MannKind apart.”
Rose Alinaya, currently the company’s Senior Vice President and Principal Accounting Officer, will take over the role of Acting Chief Financial Officer until a permanent CFO is named.
Dr. Castagna said, “I am happy to have Rose in this position as I will benefit greatly from her 14 years of experience with MannKind. She will be a key asset for me as I take on my new role.”
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya Acting Chief Financial Officer 661-775-5300 [email protected]
